Cohizon Life Sciences Limited, headquartered in India, is a prominent player in the pharmaceutical and biotechnology sectors. Founded in 2010, the company has established itself as a leader in developing innovative healthcare solutions, focusing on drug discovery, development, and manufacturing. With a strong operational presence across Asia and Europe, Cohizon Life Sciences is dedicated to advancing medical science through its cutting-edge research and development initiatives. The company offers a diverse range of core products and services, including custom synthesis, biologics, and analytical services, all distinguished by their commitment to quality and regulatory compliance. Cohizon Life Sciences has achieved significant milestones, including partnerships with leading global pharmaceutical firms, solidifying its market position as a trusted provider of life sciences solutions.
How does Cohizon Life Sciences Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cohizon Life Sciences Limited's score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cohizon Life Sciences Limited, headquartered in India, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. The company has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As there are no emissions figures or reduction initiatives available, it is unclear how Cohizon Life Sciences Limited is addressing its carbon footprint or contributing to climate action within the life sciences sector. The lack of data may suggest an opportunity for the company to develop and communicate its climate commitments more effectively, aligning with industry standards and expectations for transparency in emissions reporting.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cohizon Life Sciences Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

